UCI statement on the Vuelta a Colombia
The Union Cycliste Internationale (UCI) announces that 8 riders were notified of an Adverse Analytical Finding (AAF) in samples during the Vuelta a Colombia 2017.
The riders Luis Alberto Largo Quintero, Jonathan Felipe Paredes Hernandez, Edward Fabian Diaz Cardenas, Fabio Nelson Montenegro Forero, Luis Camargo Flechas, Fabian Robinson Lopez Rivera and Oscar Soliz Vilca were notified of an AAF of CERA* in blood samples collected on 1 and 2 August 2017.
The rider Juan Carlos Cadena Sastoque was notified of an AAF of 19-noretiocholanolone and 19-norandrosterone** in a urine sample provided on 11 August 2017.
These intelligence-led doping controls were planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling.
The riders have the opportunity to request and attend the analysis of the B sample.
In accordance with UCI Anti-Doping Rules, the riders have been provisionally suspended until the adjudication of the matter.
At this stage of the procedure, the UCI will not comment any further on any of these cases.
(*) CERA is classified as “Peptide Hormones, Growth Factors, Related Substances and Mimetics” as per the World Anti-Doping Prohibited List 2017.
(**) 19-noretiocholanolone and 19-norandrosterone are classified as “Anabolic Androgenic Steroids” as per the World Anti-Doping Prohibited List 2017.